Form 8-K - Current report:
SEC Accession No. 0001193125-24-238572
Filing Date
2024-10-17
Accepted
2024-10-17 09:12:58
Documents
13
Period of Report
2024-10-17
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d858945d8k.htm   iXBRL 8-K 43988
  Complete submission text file 0001193125-24-238572.txt   165344

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA amlx-20241017.xsd EX-101.SCH 2849
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20241017_lab.xml EX-101.LAB 17237
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20241017_pre.xml EX-101.PRE 10812
15 EXTRACTED XBRL INSTANCE DOCUMENT d858945d8k_htm.xml XML 3505
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 241376100
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)